Detalhe da pesquisa
1.
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies.
Hematol Oncol
; 40(4): 491-504, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368098
2.
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Hematol Oncol
; 38(5): 654-664, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32592408
3.
Emerging translational science discoveries, clonal approaches, and treatment trends in chronic myeloproliferative neoplasms.
Hematol Oncol
; 37(3): 240-252, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31013548
4.
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.
Hematol Oncol
; 36(5): 740-748, 2018 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-30074634
5.
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Blood
; 125(12): 1857-65, 2015 Mar 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-25624319
6.
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia.
Am J Hematol
; 92(10): 1062-1067, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28685840
7.
Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.
Haematologica
; 106(7): 1787-1793, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33657787
8.
Chronic myeloid leukemia: reminiscences and dreams.
Haematologica
; 101(5): 541-58, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27132280
9.
An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.
Haematologica
; 100(9): 1117-30, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26341525
10.
Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
EJHaem
; 5(1): 61-69, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38406504
11.
Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
J Clin Oncol
; 40(26): 3032-3036, 2022 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35820082
12.
Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
Leuk Lymphoma
; 62(11): 2568-2586, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33999767
13.
Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.
Haematologica
; 99(5): 797-801, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24790057
14.
Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
Cancers (Basel)
; 11(1)2018 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30583461
15.
Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.
Leuk Res
; 67: 67-74, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29466766
16.
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.
J Clin Invest
; 128(9): 3819-3825, 2018 08 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-29920189
17.
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Clin Lymphoma Myeloma
; 7 Suppl 2: S81-4, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17382017
18.
Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation?
Front Biosci
; 11: 198-208, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16146725
19.
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Front Biosci
; 11: 209-20, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16146726
20.
Chronic myeloid leukemia 2011: successes, challenges, and strategies--proceedings of the 5th annual BCR-ABL1 positive and BCR-ABL1 negative myeloproliferative neoplasms workshop.
Am J Hematol
; 86(9): 811-9, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21850662